<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02504619</url>
  </required_header>
  <id_info>
    <org_study_id>GC P#01.01.030</org_study_id>
    <nct_id>NCT02504619</nct_id>
  </id_info>
  <brief_title>Allogeneic SCT of CordIn™, in Patients With Hemoglobinopathies</brief_title>
  <official_title>Allogeneic Stem Cell Transplantation of CordIn™, Umbilical Cord Blood-Derived Ex Vivo Expanded Stem and Progenitor Cells, in Patients With Hemoglobinopathies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gamida Cell ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gamida Cell ltd</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      CordIn™ is a cryopreserved stem/progenitor cell-based product of purified CD133+ cells
      composed of ex vivo expanded allogeneic UCB cells. The overall study objectives are to
      evaluate the safety and efficacy of CordIn™.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      CordIn™ is a cryopreserved stem/progenitor cell-based product of purified CD133+ cells
      composed of ex vivo expanded allogeneic UCB cells.

      The trial ends when the last patient completes their last visit. The overall study objectives
      are to evaluate the safety and efficacy of CordIn™: single ex-vivo expanded cord blood unit
      transplantation in patients with hemoglobinopathies (sickle cell disease or thalassemia
      major) following a preparative therapy.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2015</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2018</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The acute toxicities associated with the infusion of CordIn, within 24 hours post-infusion.</measure>
    <time_frame>24 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>The proportion of patients with donor-derived engraftment at 42 days following transplantation</measure>
    <time_frame>42 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival at 365 days after transplantation</measure>
    <time_frame>365 days</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">15</enrollment>
  <condition>Sickle Cell Disease</condition>
  <condition>Thalassemia</condition>
  <arm_group>
    <arm_group_label>CordIn</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Transplantation of CordIn</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>CordIn</intervention_name>
    <description>CordIn™ is a cryopreserved stem/progenitor cell-based product of purified CD133+ cells composed of ex vivo expanded allogeneic UCB cells.</description>
    <arm_group_label>CordIn</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient is a candidate for allogeneic SCT for treatment of SCD or thalassemia

          -  Patients must have one partially HLA-matched CBUs

          -  Adequate Karnofsky Performance score or Lansky Play-Performance scale

          -  Sufficient physiological reserves

          -  Signed written informed consent

        Exclusion Criteria:

          -  Prior allogeneic HSCT

          -  Evidence of HIV infection or HIV positive serology

          -  Evidence of active Hepatitis B, Hepatitis C or EBV as determined by serology or PCR

          -  Active or uncontrolled infection

          -  Pregnancy or lactation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>25 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jean-Hugues Dalle, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Robert Debre, Paris, France</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Franco Locatelli, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>IRCCS Ospedale Pediatrico Bambino Gesu, Rome, Italy</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Allistair Abraham, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Children's National, Washington DC</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kelly Myers</last_name>
    <phone>+972-2-659-5631</phone>
    <email>clinicaltrials@gamida-cell.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>UCSF Benioff Children's Hospital</name>
      <address>
        <city>Oakland</city>
        <state>California</state>
        <zip>94609</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mark Walters, MD</last_name>
    </contact>
    <investigator>
      <last_name>Mark Walters, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's National</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Allistair Abraham, MD</last_name>
      <phone>202-476-3634</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital Robert Debré</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean-Hugues Dalle, MD</last_name>
      <phone>+33 1 40 03 53 88</phone>
      <email>jhugues.dalle@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Jean-Hugues Dalle, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 21, 2015</study_first_submitted>
  <study_first_submitted_qc>July 20, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 22, 2015</study_first_posted>
  <last_update_submitted>January 3, 2018</last_update_submitted>
  <last_update_submitted_qc>January 3, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 5, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anemia, Sickle Cell</mesh_term>
    <mesh_term>Thalassemia</mesh_term>
    <mesh_term>Hemoglobinopathies</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

